» Articles » PMID: 17309810

Discussing Complementary Therapies in an Oncology Setting

Overview
Date 2007 Feb 21
PMID 17309810
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

When herbal or other biologic therapies are used with conventional treatments, adverse drug-herb interactions can occur. Of course, benefits can also be derived that decrease the side effects of conventional medicine and/or support general recovery, a sense of well-being, and health. Even though people with cancer typically use complementary medicines along with conventional treatment, many of them do so without informing anyone on their health care team. This lack of discussion is of grave concern, especially for ingestible substances. This article considers some of the barriers to open communication about complementary treatments and provides support for why it is the health care professional's responsibility to bring up the topic for both medical and legal reasons. Strategies for initiating and guiding an informed dialogue are described and important resources are provided.

Citing Articles

Oncology researchers' and clinicians' perceptions of complementary, alternative, and integrative medicine: an international, cross-sectional survey.

Ng J, Kochhar J, Cramer H Support Care Cancer. 2024; 32(9):615.

PMID: 39196463 PMC: 11358342. DOI: 10.1007/s00520-024-08785-9.


Addressing Complementary and Alternative Medicine Use Among Individuals With Cancer: An Integrative Review and Clinical Practice Guideline.

Balneaves L, Watling C, Hayward E, Ross B, Taylor-Brown J, Porcino A J Natl Cancer Inst. 2021; 114(1):25-37.

PMID: 33769512 PMC: 8755493. DOI: 10.1093/jnci/djab048.


Complementary and Alternative Medicine Use in Minority and Medically Underserved Oncology Patients: Assessment and Implications.

Jones D, Cohen L, Rieber A, Urbauer D, Fellman B, Fisch M Integr Cancer Ther. 2017; 17(2):371-379.

PMID: 29025275 PMC: 6041918. DOI: 10.1177/1534735417735892.


Integrating complementary and alternative medicine into cancer care: Canadian oncology nurses' perspectives.

Truant T, Balneaves L, Fitch M Asia Pac J Oncol Nurs. 2016; 2(4):205-214.

PMID: 27981116 PMC: 5123512. DOI: 10.4103/2347-5625.167233.


[Malignant head and neck melanoma: Part 2: Therapy].

Pfohler C, Vogt T, Muller C HNO. 2015; 63(8):593-602.

PMID: 26219523 DOI: 10.1007/s00106-015-0034-5.